Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

degarelix

Degarelix Might Be Superior to Leuprolide in Minimizing Cardiovascular Disease and Incidents in Men with Prostate Cancer

We know that the incidence of both cardiovascular disease (CVD) and prostate cancer increase with age, resulting in higher mortality. CVD is the second most common cause of death in men with prostate cancer [1,2] Hormone therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists like Lupron for treatment of prostate cancer has been linked to additional increases in CVD morbidity and mortality. This link is especially evident in the first year of treatment [3], and men with a history of CVD are at higher risk [3].

Degarelix, which is different from the (GnRH) agonists, is a GnRH receptor antagonist also approved for the treatment of men with advanced prostate cancer. However, good data is suggesting that degarelix might have a lower incidence of causing CVD than the GnRH agonists

, , ,

The Difference Between Agonists, Antiandrogens, and Antagonist in ADT

, , ,

First line Hormone Therapy (ADT) involves the use of different drugs. These drugs include three different classes of medications with three different modes of action.  They include the GnRH agonists, such as leuprolide, antagonists like Firmagon and the antiandrogens like Casodex. 

Gold Guidestar Seal
Gold Transparency 2022